Clinical trial
A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection
NCT05442983 is registered in ClinicalTrials.gov with TrippBio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection
- Lead sponsor
- TrippBio, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 12, 2022
- Completion date
- October 8, 2022
- Enrollment
- 75 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.